Legal & General Group Plc Purchases 14,574 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Legal & General Group Plc grew its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 13.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 123,664 shares of the company’s stock after acquiring an additional 14,574 shares during the period. Legal & General Group Plc owned about 0.10% of Vaxcyte worth $10,123,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Whipplewood Advisors LLC acquired a new stake in Vaxcyte during the 4th quarter valued at $28,000. Smartleaf Asset Management LLC boosted its holdings in shares of Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after buying an additional 260 shares during the period. National Bank of Canada FI acquired a new position in Vaxcyte in the 4th quarter valued at about $41,000. Blue Trust Inc. raised its holdings in Vaxcyte by 100.0% in the 4th quarter. Blue Trust Inc. now owns 742 shares of the company’s stock valued at $61,000 after acquiring an additional 371 shares during the period. Finally, Assetmark Inc. lifted its position in Vaxcyte by 77,500.0% during the fourth quarter. Assetmark Inc. now owns 776 shares of the company’s stock worth $64,000 after acquiring an additional 775 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Vaxcyte

In other news, CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $86.51, for a total value of $692,080.00. Following the sale, the chief financial officer now directly owns 109,491 shares in the company, valued at approximately $9,472,066.41. This trade represents a 6.81 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 32,000 shares of company stock worth $2,638,800 over the last 90 days. Insiders own 3.10% of the company’s stock.

Vaxcyte Trading Up 5.3 %

NASDAQ PCVX opened at $30.65 on Friday. The firm’s 50 day simple moving average is $61.81 and its 200 day simple moving average is $83.64. The firm has a market capitalization of $3.95 billion, a price-to-earnings ratio of -6.66 and a beta of 1.26. Vaxcyte, Inc. has a 1 year low of $27.66 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.14. On average, equities research analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently commented on PCVX. Guggenheim reaffirmed a “buy” rating and issued a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. The Goldman Sachs Group reduced their target price on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price target on shares of Vaxcyte in a research report on Tuesday, April 8th. Evercore ISI raised shares of Vaxcyte to a “strong-buy” rating in a report on Monday, March 31st. Finally, Bank of America lowered their target price on shares of Vaxcyte from $157.00 to $137.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $136.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.